DEF: Longeveron Schedules 2026 Annual Meeting, Proposes Share Increase and Reverse Stock Split

Longeveron Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for July 1, 2026, to address key corporate actions including a significant increase in authorized shares and a reverse stock split.

Summary

• Longeveron Inc. is holding its 2026 Annual Meeting of Stockholders on July 1, 2026, virtually.
• The meeting agenda includes the election of three directors, approval to increase authorized Class A common stock from 84,295,000 to 175,000,000 shares, and approval for a reverse stock split of Class A and Class B common stock at a ratio between 1:2 and 1:20.
• Stockholders will also vote on an amendment to increase shares available under the 2021 Incentive Award Plan by 5,000,000 shares and ratify the appointment of CBIZ CPAs P.C. as the independent auditor for fiscal year 2026.
• An adjournment proposal is included to allow for further solicitation of proxies if needed for the share increase or reverse stock split proposals.
• The record date for determining stockholders entitled to vote is May 11, 2026.
• Proxy materials are expected to be mailed or made available on or about May 20, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the company is taking proactive steps to address Nasdaq listing requirements and future capital needs, the necessity of a reverse stock split and the potential for dilution indicate underlying financial pressures.

Positives

• The company is proactively addressing potential Nasdaq listing requirements by proposing a reverse stock split to increase the per-share price of its Class A common stock.
• The proposed increase in authorized shares aims to provide greater flexibility for future corporate needs, including potential acquisitions, strategic transactions, and capital raising.
• The virtual format of the annual meeting is intended to enhance accessibility for stockholders globally.
• The company is seeking to align employee and stockholder interests through amendments to its 2021 Incentive Award Plan.

Negatives

• The reverse stock split carries risks, including the possibility that it may not increase the stock price long-term, could decrease liquidity, and may result in odd lots that are more difficult to sell.
• The company has experienced several board member resignations in late 2025.
• The company's Class A common stock was trading at $0.8379 per share on the record date, below the $1.00 minimum bid price required for continued listing on Nasdaq.
• The proposed increase in authorized shares could lead to dilution of voting power and earnings per share for existing stockholders if new shares are issued.

Risks

• Failure to increase the per-share bid price through the reverse stock split could lead to delisting from Nasdaq.
• The reverse stock split may not achieve its intended effect of increasing the stock price or may only do so temporarily.
• Reduced trading volume and a smaller number of market makers could result from the reverse stock split, potentially decreasing liquidity.
• Stockholders owning odd lots after the reverse stock split may face higher transaction costs.
• The market price of Class A common stock may be volatile following the announcement of the reverse stock split, potentially allowing future investors to acquire shares at a lower price.
• The company is currently in active discussions for one or more equity or debt financings, the success and terms of which may be affected by the reverse stock split announcement and post-split price.

Future Outlook

The company is seeking stockholder approval for actions that will provide greater financial flexibility and address Nasdaq listing requirements, indicating a focus on future capital raising and operational stability. The success of these proposals is crucial for the company's continued listing and ability to pursue strategic opportunities.

Management Comments

• We believe this will enhance accessibility to our Annual Meeting for all our stockholders.
• We are pleased to embrace the current technology available to provide expanded access and enable greater stockholder attendance and participation from any location around the world.
• Your vote is important.
• The Board believes that the Share Increase Amendment is advisable and in the best interests of the Company and its stockholders.
• We believe that increasing the trading price of our Class A Common Stock may also assist in our capital-raising efforts by making our Class A Common Stock more attractive to a broader range of investors.
• The Board unanimously recommends a vote for approval of the Share Increase Amendment.
• The Board unanimously recommends a vote for the proposal to amend our Certificate of Incorporation to effect the Reverse Stock Split.
• The Board unanimously recommends a vote for approval to amend the Longeveron 2021 Incentive Award Plan.
• The Board of Directors unanimously recommends a vote for ratification of the appointment of CBIZ CPAs P.C. as our independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The Board recommends a vote for the adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are insufficient votes at the time of the Annual Meeting to approve the Authorized Share Proposal and the Reverse Stock Split Proposal.

Industry Context

StockSavvy.ai notes that Longeveron's proposed reverse stock split is a common strategy for biotechnology companies seeking to maintain Nasdaq listing compliance, especially when facing sub-$1.00 share prices. The concurrent proposal to increase authorized shares suggests an anticipation of future capital needs, which is typical for companies in this sector that often require significant funding for clinical development and commercialization.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Joshua Hare (CSO and Executive Chairman) has a consulting agreement for $265,000 annually, with deferred compensation for 2024 and 2025 to be paid in February 2027 and February 2028, respectively. He also received stock options as part of a Cash-for-Equity Program to settle accrued fees and bonuses.
• The company is a licensee under an exclusive license agreement with JMH MD Holdings, LLC (an affiliate of Dr. Hare) for CD271 cellular therapy technology, involving a 1% running royalty on net sales and potential milestone payments.
• Former Interim CEO J. Nathaniel Powell, CFO Lisa A. Locklear, and former Director Khoso Baluch participated in a public offering on August 11, 2025, though the amount involved did not exceed $120,000 for each.
• Indemnification agreements are in place with all directors and executive officers.

Stakeholder Impact

• Shareholders: Potential dilution from increased authorized shares, potential negative impact on share price and liquidity from reverse stock split, but also potential benefit from continued Nasdaq listing and improved capital raising ability.
• Employees: Continued incentive opportunities through the amended 2021 Incentive Award Plan.
• Management: Temporary compensation reductions implemented in February 2026, with subsequent repayment and RSU grants upon successful financing.
• Directors: Temporary reduction in fees implemented in February 2026, with subsequent restoration upon successful financing.

Next Steps

• Stockholders to vote on the proposed director elections, share increase, reverse stock split, incentive plan amendment, auditor ratification, and adjournment proposal at the Annual Meeting.
• If approved, the Share Increase Amendment will be filed with the Delaware Secretary of State.
• If approved, the Board will determine the timing and ratio for the Reverse Stock Split and file the amendment with the Delaware Secretary of State.
• The Board will determine the timing of the Reverse Stock Split implementation, with authority expiring December 31, 2026, if not implemented.

Key Dates

Recommendation

The company is facing critical junctures with its Nasdaq listing and capital needs. While the proposed actions aim to address these, the inherent risks of a reverse stock split and potential dilution warrant a cautious 'hold' stance. Investors should monitor the outcome of the annual meeting and the company's subsequent financing and stock performance.

Keywords

Longeveron Inc., Annual Meeting, Proxy Statement, Reverse Stock Split, Authorized Shares, Nasdaq Listing, Equity Incentive Plan, Director Election, Independent Auditor, Corporate Governance